Mark Warren

11.3k total citations · 1 hit paper
32 papers, 2.0k citations indexed

About

Mark Warren is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Mark Warren has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Mark Warren's work include Diabetes Treatment and Management (19 papers), Diabetes Management and Research (17 papers) and Pancreatic function and diabetes (9 papers). Mark Warren is often cited by papers focused on Diabetes Treatment and Management (19 papers), Diabetes Management and Research (17 papers) and Pancreatic function and diabetes (9 papers). Mark Warren collaborates with scholars based in United States, Denmark and United Kingdom. Mark Warren's co-authors include Ofri Mosenzon, Tina Vilsbøll, Stephen C. Bain, Cees J. Tack, Freddy G. Eliaschewitz, Mansoor Husain, Ildiko Lingvay, Sue D. Pedersen, Morten Donsmark and Kathleen Dungan and has published in prestigious journals such as New England Journal of Medicine, JAMA and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark Warren

30 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

2019 1.2k citations Ofri Mosenzon, Mark Warren et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Warren United States	14	1.8k	745	643	380	192	32	2.0k
Frank Vercruysse United States	19	1.7k 0.9×	583 0.8×	931 1.4×	493 1.3×	146 0.8×	24	2.1k
Lin Ping United States	8	2.2k 1.2×	919 1.2×	739 1.1×	420 1.1×	332 1.7×	11	2.4k
Robert Cuddihy United States	22	2.3k 1.3×	887 1.2×	731 1.1×	383 1.0×	177 0.9×	44	2.7k
Thomas Idorn Denmark	19	1.6k 0.9×	498 0.7×	645 1.0×	367 1.0×	281 1.5×	44	2.1k
Stefan Kaspers Germany	25	1.9k 1.0×	717 1.0×	1.1k 1.7×	162 0.4×	271 1.4×	52	2.3k
Nima Soleymanlou Canada	16	2.1k 1.1×	693 0.9×	1.3k 2.0×	241 0.6×	283 1.5×	27	3.0k
Thomas Blevins United States	23	2.3k 1.3×	724 1.0×	954 1.5×	441 1.2×	87 0.5×	55	2.6k
H.J. Woerle Germany	18	1.6k 0.9×	745 1.0×	701 1.1×	259 0.7×	126 0.7×	31	1.7k
Phil Ambery United Kingdom	18	897 0.5×	449 0.6×	399 0.6×	313 0.8×	104 0.5×	57	1.3k
Robert Josse Canada	10	1.7k 1.0×	730 1.0×	665 1.0×	251 0.7×	426 2.2×	17	2.2k

Countries citing papers authored by Mark Warren

Since Specialization

Citations

This map shows the geographic impact of Mark Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Warren more than expected).

Fields of papers citing papers by Mark Warren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Warren. The network helps show where Mark Warren may publish in the future.

Co-authorship network of co-authors of Mark Warren

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Warren. A scholar is included among the top collaborators of Mark Warren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Warren. Mark Warren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhargava, Anuj, Richard M. Bergenstal, Mark Warren, et al.. (2025). Safety and Effectiveness of MiniMed ^TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes. Diabetes Technology & Therapeutics. 27(5). 366–375. 3 indexed citations

Warren, Mark, et al.. (2024). A Scalable Application of Artificial Intelligence-Driven Insulin Titration Program to Transform Type 2 Diabetes Management. Diabetes Technology & Therapeutics. 26(8). 556–565. 4 indexed citations

Christofides, Elena A., Andrzej Stankiewicz, Douglas Denham, et al.. (2024). Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment. Endocrine Practice. 30(9). 810–816.

Watts, Nelson B., John P. Bilezikian, Henry G. Bone, et al.. (2023). Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society. 7(5). bvad043–bvad043. 5 indexed citations

Aroda, Vanita R., Robert Bauer, CHRISTIN L. HERTZ, et al.. (2020). 932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program. Diabetes. 69(Supplement_1). 7 indexed citations

Mosenzon, Ofri, Eden Miller, & Mark Warren. (2020). Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine. 132(sup2). 37–47. 10 indexed citations

Mannstadt, Michael, B.L. Clarke, John P. Bilezikian, et al.. (2019). Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 104(11). 5136–5147. 47 indexed citations

Warren, Mark, et al.. (2019). Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Current Medical Research and Opinion. 35(9). 1623–1629. 3 indexed citations

Bilezikian, John P., Henry G. Bone, B.L. Clarke, et al.. (2019). OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations

10.

Clarke, B.L., Dolores Shoback, John P. Bilezikian, et al.. (2018). Five-year efficacy and safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label race study. Endocrine Abstracts. 2 indexed citations

11.

Åhrén, Bo, Stephen L. Atkin, G. Charpentier, et al.. (2018). Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obesity and Metabolism. 20(9). 2210–2219. 101 indexed citations

12.

Leiter, Lawrence A., G. Charpentier, Louis Chaykin, et al.. (2017). Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5. Canadian Journal of Diabetes. 41(5). S6–S6. 8 indexed citations

13.

Warren, Mark, Louis Chaykin, Serge Jabbour, et al.. (2017). Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clinical Diabetes. 35(2). 90–95. 14 indexed citations

14.

Bode, Bruce W., Louis Chaykin, Allen Sussman, et al.. (2014). Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). Endocrine Practice. 20(8). 785–791. 24 indexed citations

15.

Sorli, Christopher, Mark Warren, David S. Oyer, et al.. (2013). Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials. Drugs & Aging. 30(12). 1009–1018. 40 indexed citations

16.

Nowicki, Michał, Ivan Rychlík, Hermann Haller, et al.. (2011). Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. International Journal of Clinical Practice. 65(12). 1230–1239. 108 indexed citations

17.

Nowicki, Michał, Ivan Rychlík, Hermann Haller, et al.. (2011). Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obesity and Metabolism. 13(6). 523–532. 105 indexed citations

18.

Warren, Mark. (2009). Sex Differences And Relationship Between Blood Pressure And Age Among The Ibos Of Nigeria. 3(2). 4 indexed citations

19.

Warren, Mark, Martin J. Conway, Leslie J. Klaff, Julio Rosenstock, & Elsie Allen. (2004). Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Research and Clinical Practice. 66(1). 23–29. 45 indexed citations

20.

Birken, Steven, Nanette Santoro, Galina Kovalevskaya, et al.. (1999). Differences in Urinary Excretion Patterns of the hLH Beta Core Fragment in Premenopausal, Perimenopausal, and Postmenopausal Women. Menopause The Journal of The North American Menopause Society. 6(4). 290–298. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact